Table 2.
Studies included in the meta-analysis of effect of DCS on the Y-BOCS at midtreatment
| First author | DCS group
|
Placebo group
|
Notes | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Pretreatment | Midtreatment | Decrease | Sample size (n) | Pretreatment | Midtreatment | Decrease | Sample size (n) | ||
| Kushner 200717 | 27.1±3.8 | 15.1±4.8 | 12.0±6.1 | 14 | 28.2±5.1 | 15.5±6.2 | 12.7±8.0 | 11 | Y-BOCS was given at baseline and after fourth session |
| Wilhelm 200816 | 26.5±5.0 | 12.8±6.3 | 13.7±8.0 | 10 | 25.5±4.2 | 19.0±4.1 | 6.5±5.9 | 13 | Y-BOCS was given at pretreatment and after fifth session |
| Storch 201019 | 24.1±4.4 | 15.6±6.8 | 8.5±8.1 | 15 | 26.0±3.8 | 17.9±4.5 | 8.1±5.9 | 15 | CY-BOCS was given at pretreatment and after sixth session |
| Mataix-Cols 201420 | 26.9±3.7 | 18.1±7.6 | 8.8±8.5 | 13 | 25.0±3.4 | 17.5±4.6 | 7.5±5.7 | 14 | – |
Note: Data are presented as mean ± standard deviation unless noted otherwise.
Abbreviations: DCS, D-cycloserine; Y-BOCS, Yale-Brown Obsessive Compulsive Scale; CY-BOCS, Children’s Yale-Brown Obsessive Compulsive Scale.